European Journal of Medicinal Chemistry p. 1011 - 1019 (2000)
Update date:2022-08-02
Topics:
Gaubert, Gilles
Mathe, Christophe
Imbach, Jean-Louis
Eriksson, Staffan
Vincenzetti, Silvia
Salvatori, Daniela
Vita, Alberto
Maury, Georges
Although 2'-deoxy-β-D-5-azacytidine (Decitabine) and β-D-5-azacytidine display potent antileukemic properties, their therapeutic use is hampered by their sensitivity to nucleophiles and to deamination catalysed by cytidine deaminase. As shown earlier [Shafiee M., Griffon J.-F., Gosselin G., Cambi A., Vincenzetti S., Vita A., Erikson S., Imbach J.-L., Maury G., Biochem. Pharmacol. 56 (1998) 1237-1242], β-L-enantiomers of cytidine derivatives are resistant to cytidine deaminase. We thus synthesized several 5-azacytosine β-L-nucleoside analogues to evaluate their enzymatic and biological properties. 2'-Deoxy-β-L-5-azacytidine (L-Decitabine), β-L-5-azacytidine, 1-(β-L-xylo-furanosyl)5-azacytosine, and 1-(2-deoxy-β-L-threo-pentofuranosyl)5-azacytosine were stereospecifically prepared starting from L-ribose and L-xylose. D- and L-enantiomers of 2'-deoxy-β-5-azacytidine were weak substrates of human recombinant deoxycytidine kinase (dCK) compared to β-D-deoxycytidine, whereas both enantiomers of β-5-azacytidine or the L-xylo-analogues were not substrates of the enzyme. As expected, none of the presently reported derivatives of β-L-5-azacytidine was a substrate of human recombinant cytidine deaminase (CDA). The prepared compounds were tested for their activity against HIV and HBV and they did not show any significant activity or cytotoxicity. In the case of L-Decitabine, this suggests that the enantioselectivities of concerned enzymes other than dCK and CDA might not be favourable. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
View MoreJiaxing Taixin Pharmaceutical Chemical Co., Ltd
Contact:0573-82613601
Address:Chemical Park, Jiaxing, Zhejiang, China
Tianjin Hedong Red Cliff Chemical Reagent Factory
Contact:+86-022-84780548
Address:Li Ming Zhuang Gong Ye Yuan,Dongli District,Tianjin,China
Suzhou Chiral Pharmaceuticals Co., Ltd.
Contact:86-0512-63197058
Address:Building A, No. 2358, Chang'an Road, Wujiang Science Park
Contact:+86-21-61318535
Address:Building 29,No.2139 Xizha Road, Fengxian District, Shanghai
NIGNXIA XINDACHANG TECHNOLOGY CO.,LTD
website:https://xdcchemical.com/
Contact:86-311-85758226
Address:North Industry Area, Wuji
Doi:10.1002/1521-3773(20001201)39:23<4308::AID-ANIE4308>3.0.CO;2-4
(2000)Doi:10.1016/S0040-4020(01)00893-6
(2001)Doi:10.5560/ZNB.2014-4001
(2014)Doi:10.1021/ja00787a041
(1973)Doi:10.1016/j.molstruc.2020.128461
(2020)Doi:10.1016/0040-4020(65)80030-8
(1965)